Neomorph Inc. Closes $100M Series B Financing

Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, has closed a $100 million Series B financing led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others.

“This financing is a testament to the science, strategy, and team we have built at Neomorph, and it provides us with the capital to execute on our most important near-term priorities,” said Phil Chamberlain, D.Phil., Co-Founder, President, and CEO of Neomorph. “We remain focused on executing the Phase 1/2 trial of NEO-811 to generate clinical data that will inform continued development, while advancing a broader pipeline of novel molecular glue degraders against targets that have historically been considered undruggable.”

Proceeds from the financing will primarily support the advancement of the ongoing NEO-811 Phase 1/2 trial, a first-in-human, open-label monotherapy study evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC). The capital will also support advancement of Neomorph’s pipeline across multiple therapeutic areas, driven by its proprietary platform to unlock targets that have historically been unreachable with conventional drug discovery.